Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10567568 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Ross SE, Erickson RL, Hemati N, MacDougald OA (1999) Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase. Mol Cell Biol 19, 8433-41 10567568
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T222-p - C/EBP-alpha (mouse) ▲
Orthologous residues
C/EBP‑alpha (human): T226‑p, C/EBP‑alpha (mouse): T222‑p, C/EBP‑alpha (rat): T222‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phosphoamino acid analysis
 Relevant cell lines - cell types - tissues:  293T (epithelial), 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout]
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE GSK3A (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3A (human) transfection of constitutively active enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin decrease
wortmannin increase
lithium decrease
okadaic acid lithium inhibit treatment-induced decrease
Downstream Regulation
 Effect of modification (process):  transcription, altered

T226-p - C/EBP-alpha (mouse) ▲
Orthologous residues
C/EBP‑alpha (human): T230‑p, C/EBP‑alpha (mouse): T226‑p, C/EBP‑alpha (rat): T226‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phosphoamino acid analysis
 Relevant cell lines - cell types - tissues:  293T (epithelial), 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout]
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE GSK3A (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3A (human) transfection of constitutively active enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin decrease
wortmannin increase
lithium decrease
okadaic acid lithium inhibit treatment-induced decrease
Downstream Regulation
 Effect of modification (process):  transcription, altered

S230-p - C/EBP-alpha (mouse) ▲
Orthologous residues
C/EBP‑alpha (human): S234‑p, C/EBP‑alpha (mouse): S230‑p, C/EBP‑alpha (rat): S230‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phosphoamino acid analysis
 Relevant cell lines - cell types - tissues:  293T (epithelial), 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout]
 Cellular systems studied:  cell lines
 Species studied:  human, mouse


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.